RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles announced today that it will contribute a total of $2.6 million over four years to support I-SPY 2, a unique adaptive clinical trial designed to develop breast cancer therapies twice as quickly and at one-fifth the cost of current methods. Current development costs typically exceed $1 billion and take 12 to 15 years to bring a single drug to market.
